Vasopressin is a nonapeptide produced in the hypothalamus, exhibits diverse physiological functions related to hemodynamic modulation, diuresis, and behavior. Vasopressin is similar to oxytocin, differing in the third and eight amino acid.

Vasopressin is indicated for the treatment of postoperative abdominal distention, abdominal roentgenography, Gastrointestinal Bleeding and diabetes insipidus.

Market Dynamics

The increasing approvals of vasopressin drug by regulatory authorities is expected to drive the global vasopressin market growth. For instance, in 2018, Eagle Pharmaceuticals, Inc., received abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration for its vasopressin injection, 1ml. Vasostrict had around US$ 400 million in brand sales in 2017, according to the Eagle Pharmaceuticals, Inc., company financial review.

Key features of the study

• This report provides in-depth analysis of the global vasopressin market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global vasopressin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global vasopressin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vasopressin market

Market Segmentation

• By Type (Revenue, USD Bn, 2021-2033)
  • Intravenous Injection
  • Intramuscular Injection
  • Subcutaneous Injection
• By Application (Revenue, USD Bn, 2021-2033)
  • Anti-Diuretic Hormone Deficiency
  • Gastrointestinal Bleeding
  • Vasodilatory Shock
  • Ventricular Tachycardia & Fibrillation
• By End User (Revenue, USD Bn, 2021-2033)
  • Hospitals
  • Clinics
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Par Pharmaceutical
  • Pfizer Inc.
  • Novartis AG
  • Ferring Pharmaceuticals
  • Fresenius Kabi Canada
  • Astellas Pharma
  • Shanghai Soho-Yiming Pharmaceuticals
  • Endo International
  • Hybio Pharmaceutical
  • Hainan Zhonghe Pharmaceutical
  • Cumberland Pharmaceuticals